Schedule Dispatches

This is an early notification of the changes to be announced in the Update to the Pharmaceutical Schedule.

The full Update is available as a PDF(external link)

The changes will be published in the online Schedule around the 23^rd of this month and are effective from next month.

For any questions about these listing changes or the Pharmaceutical Schedule in general, email us at enquiry@pharmac.govt.nz

New Listings

• Atropine sulphate (Hikma) inj 600 mcg per ml, 1 ml ampoule – up to 5 inj available on a PSO, s29 and wastage claimable (p’code 2693976)
• Budesonide with glycopyrronium and eformoterol (Breztri Aerosphere) aerosol inhaler budesonide 160 mcg with glycopyrronium 7.2 mcg and formoterol 5 mcg per dose, 120 dose OP – Special Authority – Retail pharmacy (p’code 2656841)
• Calcitriol (Calcitriol-AFT S29) cap 0.25 mcg – s29 and wastage claimable (p’code 2695154)
• Covid-19 vaccine (Comirnaty Omicron (JN.1)) inj 10 mcg bretovameran per 0.3 ml, 0.48 ml vial; paediatric vaccine, light blue cap (p’code 2697386); inj 3 mcg bretovameran per 0.3 ml, 0.48 ml vial; infant vaccine, yellow cap (p’code 2697378) and inj 30 mcg bretovameran per 0.3 ml, 0.48 ml vial; adult vaccine, light grey cap (p’code 2697394) – Xpharm, access criteria applies
• Cytarabine (Pfizer) inj 20 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist (p’code 2695758)
• Eftrenonacog alfa [recombinant factor IX] (Alprolix) inj 250 iu vial (p’code 2696150), inj 500 iu vial (p’code 2696169), inj 1,000 iu vial (p’code 2696177), inj 2,000 iu vial (p’code 2696185), inj 3,000 iu vial (p’code 2696193) and inj 4,000 iu vial (p’code 2696207) – Xpharm
• Flecainide acetate (Tambocor German) inj 10 mg per ml, 15 ml ampoule – s29 and wastage claimable (p’code 2696967) 
• Osimertinib (Tagrisso) tab 40 mg (p’code 2536358) and tab 80 mg (p’code 2536331) – Special Authority – Retail pharmacy
• Palivizumab (Synagis) inj 100 mg per ml, 1 ml vial – PCT only – Special Authority (p’code 2621835)
• Promethazine hydrochloride (Phenergan Elixir) oral liq 1 mg per ml, 100 ml (p’code 692700)
• Risperidone (Risperdal) tab 4 mg – Safety medicine (p’code 245402)
• Sodium fusidate [fusidic acid] (Fucithalmic S29) eye drops 1%, 5 g OP – s29 (p’code 2697572)
• Solifenacin succinate (Solifenacin succinate Max Health) tab 5 mg (p’code 2690608) and tab 10 mg (p’code 2690616)
• Trastuzumab deruxtecan inj 100 mg per ml, 1 ml vial (Enhertu) (p’code 2678276) and inj 1 mg for ECP (Baxter) (p’code 2697610) – PCT only – Special Authority

Changes to restrictions, chemical names and presentations

• Atorvastatin (Lorstat) tab 10 mg, 20 mg, 40 mg and 80 mg – removal of stat dispensing
• Continuous glucose monitor (interoperable) sensor (9) and transmitter (Dexcom G6), sensor (Dexcom G7) and sensor (Freestyle Libre 3 Plus) – removal of brand switch fee
• Continuous glucose monitor (standalone) sensor (Dexcom ONE+) and sensor (Freestyle Libre 2) – removal of brand switch fee
• Durvalumab inj 50 mg per ml, 2.4 ml and 10 ml vial (Imfinzi) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
• Erlotinib (Alchemy) tab 100 mg and 150 mg – amended Special Authority criteria
• Ethinyloestradiol with norethisterone (Alyacen) tab 35 mcg with norethisterone 1 mg and 7 inert tab – removal of s29 and wastage claimable
• Ethinyloestradiol with norethisterone (Alyacen and Brevinor 1/28) tab 35 mcg with norethisterone 1 mg and 7 inert tab – removal of brand switch fee
• Gefitinib (Iressa) tab 250 mg – amended Special Authority criteria
• Itraconazole (Itraconazole Kent) oral liq 10 mg per ml, 150 ml OP – amended brand name
• Methadone hydrochloride tab 5 mg (Methadone BNM), oral liq 2 mg per ml, 200 ml (Biodone), oral liq 5 mg per ml, 200 ml (Biodone Forte), oral liq 10 mg per ml, 200 ml (Biodone Extra Forte) and inj 10 mg per ml, 1 ml (AFT) – removal of note
• Norethisterone (Norethinderone – CDC, Noriday and Noriday 28) tab 350 mcg – removal of brand switch fee
• Pegfilgrastim (Ziextenzo AU) inj 6 mg per 0.6 ml syringe – removal of s29 and wastage claimable
• Trastuzumab emtansine inj 100 mg and 160 mg vial (Kadcyla) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
• Venlafaxine (Enlafax XR) cap 37.5 mg, 75 mg and 150 mg – removal of stat dispensing

Increased subsidy

Chemical	Presentation	Fully subsidised brands
Amiloride hydrochloride	Oral liq 1 mg per ml, 25 ml OP	Biomed
Caffeine citrate	Oral liq 20 mg per ml (10 mg base per ml), 25 ml OP	Biomed
Cetirizine hydrochloride	Oral liq 1 mg per ml, 200 ml	Histaclear
Clomipramine hydrochloride	Cap 10 mg and 25 mg	Clomipramine Teva
Chlorothiazide	Oral liq 50 mg per ml, 25 ml OP	Biomed
Cyclopentolate hydrochloride	Eye drops 1%, 15 ml OP	Cyclogyl
Dexamethasone	Oral liq 1 mg per ml, 25 ml OP	Biomed
Econazole nitrate	Crm 1%, 20 g OP	Pevaryl
Erythromycin ethyl succinate	Tab 400 mg and Grans for oral liq 200 mg and 400 mg per 5 ml, 100 ml	E-Mycin
Folic acid	Oral liq 50 mcg per ml, 25 ml OP	Biomed
Hydrocortisone acetate	Rectal foam 10%, CFC-Free (14 applications), 15 g OP	Colifoam
Iron polymaltose	Inj 50 mg per ml, 2 ml ampoule	Ferrosig
Lidocaine [lignocaine] hydrochloride	Inj 1%, 5 ml ampoule and Inj 2%, 5 ml ampoule	Lidocaine-Baxter
Methylphenidate hydrochloride	Tab immediate-release 10 mg	Ritalin
Methylphenidate hydrochloride extended-release	Cap modified-release 10 mg, 20 mg, 30 mg and 40 mg	Ritalin LA
Mifepristone	Tab 200 mg	Mifegyne
Potassium citrate	Oral liq 3 mmol per ml, 200 ml OP	Biomed
Spironolactone	Oral liq 5 mg per ml, 25 ml OP	Biomed
Sodium bicarbonate	Inj 8.4%, 50 ml and 100 ml	Biomed
Sodium chloride	Inj 23.4% (4 mmol/ml), 20 ml ampoule Soln 7%, 90 ml OP	Biomed
Tropicamide	Eye drops 0.5% and 1%, 15 ml OP	Mydriacyl

Decreased subsidy        

Chemical	Presentation	Fully subsidised brands
Mitomycin C	Inj 5 mg vial	Mitomycin (Fresenius Kabi)